Document Detail


A molecular variant of angiotensinogen is associated with idiopathic intrauterine growth restriction.
MedLine Citation:
PMID:  12576245     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Intrauterine growth restriction has been associated with failed maternal physiologic changes such as abnormal spiral artery remodeling and reduced maternal blood volume. A polymorphism of angiotensinogen Thr235 has been considered a risk factor for preeclampsia. We genotyped maternal and fetal deoxyribonucleic acid (DNA) for angiotensinogen Thr235 to estimate whether the polymorphism is also a risk factor for intrauterine growth restriction. METHODS: We examined maternal blood DNA in 174 patients with intrauterine growth restriction and 60 patients with both preeclampsia and intrauterine growth restriction. The control group comprised 400 consecutive cases of women with term pregnancies and infants with birth weight between the fifth and 95th percentiles. We also examined 162 DNA samples from fetal blood with intrauterine growth restriction for the Thr235 polymorphism, and 240 normal fetuses were used as the control group. The angiotensinogen genotype was determined using mutagenically separated polymerase chain reaction. The products were size fractionated on an agarose gel. Angiotensinogen genotypes were divided into three groups: MM (homozygous for angiotensinogen Met235 allele), TT (homozygous for angiotensinogen Thr235 allele), and MT (heterozygous). RESULTS: Maternal genotyping revealed a significantly higher Thr235 allele frequency in intrauterine growth restriction (.60) and preeclampsia/intrauterine growth restriction (.63) than in the control group (.36) (P <.001). Fetal genotyping revealed a Thr235 allele frequency of.59 in intrauterine growth restriction fetuses, as compared with the control group (.38) (P <.001). CONCLUSION: Maternal and fetal angiotensinogen Thr235 genotypes are associated with an increased risk of intrauterine growth restriction in our study population. The angiotensinogen Thr235 allele may predispose women to deliver growth-restricted fetuses.
Authors:
Xiu Quan Zhang; Michael Varner; Donna Dizon-Townson; Francis Song; Kenneth Ward
Related Documents :
16819375 - The relationship between somatic growth and in vivo esophageal segmental and sphincteri...
8035245 - Intrauterine growth retardation. etiology, diagnosis, and management.
10423805 - Single and serial estimates of amniotic fluid volume and umbilical artery resistance in...
19276405 - Review: antenatal glucocorticoid treatment of the growth-restricted fetus: benefit or c...
6834185 - Effect of mild iron deficiency on infant mental development scores.
15513505 - Further examination of infants referred from newborn hearing screening.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  101     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-10     Completed Date:  2003-03-12     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  237-42     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Alleles
Angiotensinogen / genetics*
Base Sequence
Case-Control Studies
Female
Fetal Growth Retardation / epidemiology,  genetics*
Gene Frequency
Genetic Variation*
Genotype
Humans
Molecular Sequence Data
Polymerase Chain Reaction
Polymorphism, Genetic*
Pre-Eclampsia / epidemiology,  genetics*
Pregnancy
Pregnancy Outcome*
Prenatal Care
Prenatal Diagnosis
Prevalence
Probability
Reference Values
Risk Assessment
Sensitivity and Specificity
Grant Support
ID/Acronym/Agency:
1R01-HD 32170-01/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
11002-13-4/Angiotensinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibin-A and superimposed preeclampsia in women with chronic hypertension.
Next Document:  Low-dose mifepristone for uterine leiomyomata.